Prospects for the next anti-Pseudomonas drug
- PMID: 19748829
- DOI: 10.1016/j.coph.2009.08.006
Prospects for the next anti-Pseudomonas drug
Abstract
Pseudomonas aeruginosa is one of the most dreaded Gram-negative bacterial pathogens in hospitals. Not only it is among the most frequently isolated Gram-negative organisms in bloodstream and wound infections, pneumonia, intra-abdominal-sepsis and urogenital-sepsis, but also it is frequently found in patients with comorbid illnesses and compromised by in-dwelling catheters, tubes and surgery where mortality rates of more than 60% have been reported. Besides its intrinsic resistance to a number of widely used antibiotics, Pseudomonas also managed to acquire resistance via additional mechanisms, including target mutations, increased expression of efflux pumps and of antibiotic-degrading enzymes. Taken together, the increased incidence in certain types of infections, the increased use of invasive devices in the hospital as well as the increased frequency of multi-resistant Pseudomonas strains, have clearly led to a shortage of treatment options for nosocomial Pseudomonas infections. Even the recommended combination therapy of an antibiotic of the beta-lactam class together with an aminoglycoside or a fluoroquinolone, is no longer always successful and sometimes a polymyxin has to be given as last resort. Despite growing concerns of clinicians and medical societies about the very limited number of novel drugs in the pipeline to fight multi-resistant Pseudomonas strains, only a very small number of novel anti-Pseudomonas drugs are currently in late stage of pre-clinical or clinical development. However, and possibly as a reflection of the magnitude of the problem, quite a variety of approaches are being pursued. Among these are next-generation analogues of successful antibiotic classes (e.g. novel beta-lactams and combinations of novel beta-lactamase inhibitors with known penicillins or cephalosporins), antibodies, phages and selective peptides. It is to be hoped that a number of these novel drugs will show clinical utility and reach the market over the next 6-10 years.
Similar articles
-
Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.Pharmacotherapy. 2005 Oct;25(10):1353-64. doi: 10.1592/phco.2005.25.10.1353. Pharmacotherapy. 2005. PMID: 16185180 Review.
-
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.Clin Microbiol Infect. 2007 Jun;13(6):560-78. doi: 10.1111/j.1469-0691.2007.01681.x. Epub 2007 Jan 31. Clin Microbiol Infect. 2007. PMID: 17266725 Review.
-
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.Clin Microbiol Infect. 2005 Jul;11 Suppl 4:17-32. doi: 10.1111/j.1469-0691.2005.01161.x. Clin Microbiol Infect. 2005. PMID: 15953020 Review.
-
Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?Int J Antimicrob Agents. 2007 Nov;30(5):458-62. doi: 10.1016/j.ijantimicag.2007.05.022. Epub 2007 Aug 20. Int J Antimicrob Agents. 2007. PMID: 17703923
-
The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S43-8. doi: 10.1086/504476. Clin Infect Dis. 2006. PMID: 16894514 Review.
Cited by
-
Modification and Synergistic Studies of a Novel Frog Antimicrobial Peptide against Pseudomonas aeruginosa Biofilms.Antibiotics (Basel). 2024 Jun 21;13(7):574. doi: 10.3390/antibiotics13070574. Antibiotics (Basel). 2024. PMID: 39061256 Free PMC article.
-
Inhibition of Pseudomonas aeruginosa and Mycobacterium tuberculosis disulfide bond forming enzymes.Mol Microbiol. 2019 Apr;111(4):918-937. doi: 10.1111/mmi.14185. Epub 2019 Mar 18. Mol Microbiol. 2019. PMID: 30556355 Free PMC article.
-
The Anti-Microbial Peptide Citrocin Controls Pseudomonas aeruginosa Biofilms by Breaking Down Extracellular Polysaccharide.Int J Mol Sci. 2024 Apr 8;25(7):4122. doi: 10.3390/ijms25074122. Int J Mol Sci. 2024. PMID: 38612931 Free PMC article.
-
Small molecule screen yields inhibitors of Pseudomonas homoserine lactone-induced host responses.Cell Microbiol. 2014 Jan;16(1):1-14. doi: 10.1111/cmi.12176. Epub 2013 Aug 22. Cell Microbiol. 2014. PMID: 23910799 Free PMC article.
-
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10. Lancet Infect Dis. 2010. PMID: 20705517 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical